SMO and skin basal cell carcinoma: To this day, two SMO protein inhibitors have received approval from the Food and Drug Administration (FDA) for BCC treatment, namely, LDE225/Sonidegib and GDC-0449/Vismodegib, while at the same time, several clinical trials have evaluated their efficacy as directed therapy for neoplasms of the prostate (phase II), pancreas (phase II), breast (phase I), and lung (phase I/II) [13, 74].